title: The state of differentiation of HT-29 colon carcinoma cells alters the secretion of cathepsin D and of plasminogen activator.
abstract: We have studied the cellular content and the extracellular release of cathepsins B and D, and of plasminogen activator, in 2 different tumor cell populations before confluence and after late confluence: the HT-29 colon carcinoma cell line, which contains primarily undifferentiated cells, and a subpopulation derived from this cell line, which contains cells committed to differentiation into mucus-secreting goblet cells after confluence. In both populations, cellular cathepsin-B activity increased after confluence, and latent cathepsin B was found in all culture media. In the parental cell line, cellular cathepsin D activity decreased after confluence; however, cathepsin D was secreted at high levels into the extracellular medium. In contrast, in the subpopulation of cells committed to differentiation, cellular cathepsin D activity increased after confluence, and cathepsin D was not secreted into the extracellular medium, but was immunolocalized in the apical brush border of the differentiated cells. Plasminogen activator of urokinase type was identified by immunocytochemistry. Both subconfluent cell populations, and the post-confluent undifferentiated cell population, produced plasminogen activator activity at similar levels. In contrast, in the differentiated postconfluent cells, the production of plasminogen activator activity was markedly lower. Our data show that the differentiation of HT-29 colon carcinoma cells into mucus-secreting cells impairs the secretion of plasminogen activator and cathepsin D, but does not affect cathepsin B.
authors.affiliation: Laboratoire de Biochimie, Hôpital Claude Huriez, CHRU Lille, France.
authors.forename: G
authors.initials: G
authors.lastname: Huet
authors.forename: F
authors.initials: F
authors.lastname: Zerimech
authors.forename: M C
authors.initials: MC
authors.lastname: Dieu
authors.forename: B
authors.initials: B
authors.lastname: Hemon
authors.forename: G
authors.initials: G
authors.lastname: Grard
authors.forename: M
authors.initials: M
authors.lastname: Balduyck
authors.forename: A
authors.initials: A
authors.lastname: Janin
authors.forename: R
authors.initials: R
authors.lastname: Lafyatis
authors.forename: P
authors.initials: P
authors.lastname: Degand
mesh_terms: D002277:Carcinoma / Q000201:enzymology* / Q000473:pathology; D002401:Cathepsin B / Q000378:metabolism; D002402:Cathepsin D / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D003110:Colonic Neoplasms / Q000201:enzymology* / Q000473:pathology; D018819:Dipeptidyl Peptidase 4; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / Q000378:metabolism; D006801:Humans; D008727:Methotrexate / Q000494:pharmacology; D009093:Mucus; D010960:Plasminogen Activators / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; D018819:Dipeptidyl Peptidase 4; D010960:Plasminogen Activators; D002401:Cathepsin B; D002402:Cathepsin D; D008727:Methotrexate